# Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer with Different HER2 Expression Patterns

> **NCT06551220** · — · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 800 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Trastuzumab Deruxtecan

## Key facts

- **NCT ID:** NCT06551220
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-10
- **Primary completion:** 2025-01
- **Final completion:** 2025-01
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2024-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06551220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06551220, "Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer with Different HER2 Expression Patterns". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06551220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*